60.91
price up icon0.59%   0.36
pre-market  시장 영업 전:  60.91  
loading

Incyte Corp 주식(INCY)의 최신 뉴스

pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Women in healthcare and life sciences - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com

Mar 31, 2025
pulisher
Mar 30, 2025

Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener

Mar 30, 2025
pulisher
Mar 27, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 26, 2025
pulisher
Mar 24, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks

Mar 24, 2025
pulisher
Mar 23, 2025

Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte stock price target cut to $72 at Truist Securities - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte divulges new MRGPRX2 antagonists - BioWorld MedTech

Mar 18, 2025
pulisher
Mar 18, 2025

Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair cuts Incyte stock rating post-trial results - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim Downgrades Incyte to Neutral From Buy -March 18, 2025 at 06:41 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating - MarketScreener

Mar 18, 2025
pulisher
Mar 18, 2025

Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating -March 18, 2025 at 05:45 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (INCY) to Market Perform - StreetInsider.com

Mar 18, 2025
pulisher
Mar 17, 2025

Incyte stock dives after drug trial disappoints investors - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch

Mar 17, 2025
pulisher
Mar 17, 2025

RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Why Incyte (INCY) Stock Is Nosediving - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com

Mar 17, 2025
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
자본화:     |  볼륨(24시간):